CR10348A - Composicion inmunogenica - Google Patents

Composicion inmunogenica

Info

Publication number
CR10348A
CR10348A CR10348A CR10348A CR10348A CR 10348 A CR10348 A CR 10348A CR 10348 A CR10348 A CR 10348A CR 10348 A CR10348 A CR 10348A CR 10348 A CR10348 A CR 10348A
Authority
CR
Costa Rica
Prior art keywords
immunogenic composition
type
acetylated
acetylation
aureus
Prior art date
Application number
CR10348A
Other languages
English (en)
Inventor
Denoel Philippe
Poolman Jan
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0606416A external-priority patent/GB0606416D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CR10348A publication Critical patent/CR10348A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente solicitud se refiere a composiciones inmunogenicas que comprenden el polisacarido u oligosacarido capsular tipo 5 y7u 8 de s. aureus, que esta entre 30-100% 0-acetilado. Tambien se describen vacunas, metodos de tratamiento y procesos que se utilizan para fabricar una composicion inmunogenica que comprende polisacaridos capsulares tipo 5 y/u 8 con 30-100% de 0-acetilacion.
CR10348A 2006-03-30 2008-10-07 Composicion inmunogenica CR10348A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78724906P 2006-03-30 2006-03-30
US78758706P 2006-03-30 2006-03-30
GB0606416A GB0606416D0 (en) 2006-03-30 2006-03-30 Immunogenic composition

Publications (1)

Publication Number Publication Date
CR10348A true CR10348A (es) 2008-10-29

Family

ID=38515803

Family Applications (2)

Application Number Title Priority Date Filing Date
CR10348A CR10348A (es) 2006-03-30 2008-10-07 Composicion inmunogenica
CR20150097A CR20150097A (es) 2006-03-30 2015-02-25 Composición inmunogénica

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20150097A CR20150097A (es) 2006-03-30 2015-02-25 Composición inmunogénica

Country Status (19)

Country Link
US (2) US20100021503A1 (es)
EP (4) EP2476433A1 (es)
JP (1) JP2009531387A (es)
KR (1) KR101541383B1 (es)
CN (1) CN103169960A (es)
AU (2) AU2007233705B2 (es)
BR (1) BRPI0710210A2 (es)
CA (1) CA2647441C (es)
CR (2) CR10348A (es)
EA (2) EA015833B1 (es)
IL (2) IL193565A (es)
MA (1) MA30343B1 (es)
MX (1) MX337528B (es)
MY (1) MY148405A (es)
NO (1) NO20083722L (es)
NZ (2) NZ595178A (es)
SG (1) SG170090A1 (es)
WO (1) WO2007113222A2 (es)
ZA (1) ZA200808246B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2648046T3 (es) 2002-11-12 2017-12-28 The Brigham And Women's Hospital, Inc. Vacuna de polisacárido para infecciones estafilocócicas
PT2351578T (pt) * 2005-06-27 2017-04-07 Glaxosmithkline Biologicals Sa Processo para o fabrico de vacinas
US8146781B2 (en) * 2007-08-09 2012-04-03 Huhtamaki, Inc. Dispenser for viscous condiments
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2009029831A1 (en) 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
WO2009111337A1 (en) 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
EA201001478A1 (ru) * 2008-04-16 2011-06-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌(Lawsonia intracellularis)用疫苗
CN105085349B (zh) * 2008-07-21 2018-02-09 布赖汉姆妇女医院 与合成的β‑1,6 葡糖胺寡糖相关的方法和组合物
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
KR101773368B1 (ko) 2009-04-03 2017-08-31 유니버시티 오브 시카고 단백질 A(SpA) 변이체와 관련된 조성물 및 방법
SG175092A1 (en) 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
TWI469789B (zh) * 2009-06-22 2015-01-21 Wyeth Llc 金黃色葡萄球菌抗原之免疫原性組合物
RU2531234C2 (ru) * 2009-06-22 2014-10-20 ВАЙЕТ ЭлЭлСи КОНЪЮГАТ ПОЛИСАХАРИД-БЕЛОК ДЛЯ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ЗАЩИТЫ ПРОТИВ ИНФЕКЦИИ Staphylococcus aureus, СПОСОБЫ ПОЛУЧЕНИЯ КОНЪЮГАТА (ВАРИАНТЫ), КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ КОНЪЮГАТ И СПОСОБЫ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ Staphylococcus aureus
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為tlr活性調節劑之化合物及組合物
CN102844047B (zh) 2009-09-02 2017-04-05 诺华股份有限公司 含tlr活性调节剂的免疫原性组合物
JP2013506651A (ja) 2009-09-30 2013-02-28 ノバルティス アーゲー Staphylococcus.aureus5型および8型莢膜多糖の結合体
PT2493498T (pt) * 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
AU2010339921B2 (en) 2009-12-15 2016-08-11 Glaxosmithkline Biologicals S.A. Homogeneous suspension of immunopotentiating compounds and uses thereof
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインA(SpA)抗体に関連する組成物および方法
CA2797052A1 (en) * 2010-04-23 2011-10-27 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphyloccocus vaccine
KR20130063510A (ko) 2010-05-06 2013-06-14 글리코박신 아게 캡슐형 그람-양성 세균 생체접합체 백신
CN103037885B (zh) 2010-07-02 2015-08-26 芝加哥大学 与蛋白A(SpA)变体相关的组合物和方法
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 感染防御ブドウ球菌抗原が関与する方法および組成物
JP5557328B2 (ja) * 2010-10-07 2014-07-23 Nok株式会社 中空糸炭素膜の製造方法
EP2654784B1 (en) * 2010-12-22 2016-12-07 Wyeth LLC Stable immunogenic compositions of staphylococcus aureus antigens
CN103561762A (zh) * 2011-03-16 2014-02-05 明尼苏达大学董事会 诱导针对葡萄球菌属中细菌的免疫应答的组合物和方法
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
CN103857387B (zh) 2011-06-02 2017-03-15 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
CA2845259A1 (en) 2011-08-15 2013-02-21 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
CA2865620A1 (en) 2012-03-05 2013-09-12 University Of Maryland, Baltimore Multivalent vaccine protection from staphylococcus aureus infection
EP2636750A1 (en) 2012-03-06 2013-09-11 Roche Diagniostics GmbH Compatible solute ectoine as well as derivatives thereof for enzyme stabilization
CA2910320A1 (en) 2012-04-26 2013-10-31 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
EP2844275B1 (en) 2012-04-26 2020-05-13 University of Chicago Staphylococcal coagulase antigens and methods of their use
EP2950819B1 (en) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermal delivery of immunological compositions comprising toll-like receptor agonists
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
WO2015021390A2 (en) 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
US20170000875A1 (en) * 2013-12-02 2017-01-05 Arytha Biosciences, Llc Toxoid preparation and uses thereof
WO2015143295A2 (en) 2014-03-20 2015-09-24 The Regents Of The University Of California Hydrogel compositions containing toxin-absorbing or binding nanoparticles and uses thereof
BE1023004A1 (fr) 2014-12-10 2016-10-31 Glaxosmithkline Biologicals Sa Procede de traitement
WO2016176041A1 (en) 2015-04-29 2016-11-03 The Regents Of The University Of California Detoxification using nanoparticles
GB201600075D0 (en) * 2016-01-03 2016-02-17 Glaxosmithkline Biolog Sa Immunogenci composition
JP7117244B2 (ja) * 2016-02-12 2022-08-12 ザ・ユニバーシティ・オブ・シカゴ 黄色ブドウ球菌疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
AU2018329671B2 (en) * 2017-09-05 2023-12-07 Scarab Genomics, Llc Methods and compositions for improved expression of recombinant proteins
EA202091931A1 (ru) 2018-02-12 2020-11-05 Иниммьюн Корпорейшн ЛИГАНДЫ Toll-ПОДОБНЫХ РЕЦЕПТОРОВ
JP2022546812A (ja) * 2019-08-27 2022-11-09 アロペックス・インコーポレイテッド 抗菌性ワクチン組成物
US11173199B2 (en) 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
US11473093B2 (en) 2020-11-04 2022-10-18 Eligo Bioscience Cutibacterium acnes recombinant phages, method of production and uses thereof

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JP2851288B2 (ja) 1987-06-05 1999-01-27 アメリカ合衆国 癌診断および管理における自己分泌運動性因子
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5425946A (en) * 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
CN1119026A (zh) 1993-02-05 1996-03-20 史密丝克莱恩比彻姆有限公司 纤连蛋白结合蛋白;单克隆抗体以及它们对防止细菌粘附的应用
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
PT729473E (pt) 1993-11-17 2001-02-28 Deutsche Om Arzneimittel Gmbh Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
EP1167377B2 (en) 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
JPH11514870A (ja) 1995-10-16 1999-12-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規な唾液結合タンパク質
GB9521146D0 (en) 1995-10-16 1995-12-20 Smithkline Beecham Plc Novel compounds
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
ES2252785T3 (es) 1996-05-16 2006-05-16 THE TEXAS A&M UNIVERSITY SYSTEM Composiciones proteinicas fijadoras de colageno y metodos de utilizacion.
ZA975326B (en) 1996-06-18 1998-01-14 Alza Corp Device and method for enhancing transdermal flux of agents being delivered or sampled.
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ES2195190T3 (es) 1996-12-20 2003-12-01 Alza Corp Dispositivo y metodo para mejorar el flujo de agente transdermico.
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CA2310217A1 (en) 1997-11-26 1999-06-03 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
NZ504894A (en) 1997-12-02 2002-12-20 Powderject Vaccines Inc Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
HUP0102332A3 (en) 1998-06-08 2002-11-28 Sca Emballage France Fast flattening packaging
ATE355266T1 (de) 1998-06-30 2006-03-15 Om Pharma Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen
DE69941454D1 (de) 1998-07-10 2009-11-05 U S Medical Res Inst Of Infect Impfstoff gegen staphylokokken-vergiftung
ATE395931T1 (de) * 1998-07-15 2008-06-15 Brigham & Womens Hospital Polysaccharid-impfstoff gegen staphylokokken infektionen
CA2341018C (en) 1998-08-31 2012-07-31 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
ES2322409T3 (es) * 1998-08-31 2009-06-19 Inhibitex, Inc. Vacunas multicomponentes contra staphylococcus aureus.
CA2341177A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
ES2321892T3 (es) 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
CA2773698C (en) 1998-10-16 2015-05-19 Glaxosmithkline Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
HU228499B1 (en) * 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
AU1478301A (en) 1999-11-09 2001-06-06 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
SE0000514D0 (sv) 2000-02-17 2000-02-17 Biostapro Ab A 52 kDa protein from coagulase negative staphylococci and fragments
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
NZ523851A (en) 2000-07-21 2004-09-24 Ortho Mcneil Pharm Inc A method for use of carbamate enantiomers in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
ES2298269T3 (es) 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales.
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US20020169288A1 (en) 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
CA2453937C (en) 2001-08-02 2013-05-14 University Of Sheffield Antigenic polypeptides
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US7157443B2 (en) 2001-12-11 2007-01-02 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
CA2478029A1 (en) 2002-03-05 2003-09-18 Inhibitex, Inc. Monoclonal and polyclonal antibodies recognizing coagulase-negative staphylococcal proteins
WO2004015099A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine composition comprising lipooligosaccharide with reduced phase variability
AU2003249851A1 (en) * 2002-10-03 2004-04-23 Intercell Ag Use of molecules which interact with the haptoglobin receptor ligand binding
ES2648046T3 (es) 2002-11-12 2017-12-28 The Brigham And Women's Hospital, Inc. Vacuna de polisacárido para infecciones estafilocócicas
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
CN1787839B (zh) * 2003-03-07 2011-09-28 惠氏控股公司 用于抗医院内感染的免疫的多糖-葡萄球菌表面粘附素载体蛋白缀合物
JP4764820B2 (ja) * 2003-06-23 2011-09-07 バクスター・インターナショナル・インコーポレイテッド ワクチン用担体タンパク質
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1725575B1 (en) * 2004-02-18 2012-11-28 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against staphylococcus aureus
NZ551250A (en) 2004-05-11 2010-03-26 Nederlanden Staat Neisseria meningitidis 1gtB LOS as adjuvant
EP2305294B1 (en) * 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
KR20070085457A (ko) 2004-10-25 2007-08-27 더 유니버시티 오브 웨스턴 온타리오 스태필로코쿠스 아우레우스의 철에 의해 조절되는 표면결정인자 IsdA, IsdB, 및 IsdC 기재 백신,조성물 및 방법
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan

Also Published As

Publication number Publication date
EA020459B1 (ru) 2014-11-28
AU2011201158A1 (en) 2011-04-07
MX2008012405A (es) 2008-10-07
ZA200808246B (en) 2014-11-26
IL193565A0 (en) 2009-08-03
CA2647441C (en) 2021-02-23
EP3141261A1 (en) 2017-03-15
NZ595178A (en) 2013-03-28
MA30343B1 (fr) 2009-04-01
KR101541383B1 (ko) 2015-08-03
IL227934A0 (en) 2013-09-30
WO2007113222A3 (en) 2007-11-29
CR20150097A (es) 2015-04-14
SG170090A1 (en) 2011-04-29
AU2011201158B2 (en) 2013-08-22
EP2476433A1 (en) 2012-07-18
EP1998802A2 (en) 2008-12-10
NZ570805A (en) 2011-10-28
IL193565A (en) 2013-10-31
CN103169960A (zh) 2013-06-26
AU2007233705A1 (en) 2007-10-11
CA2647441A1 (en) 2007-10-11
EA200801839A1 (ru) 2009-08-28
MX337528B (es) 2016-03-09
BRPI0710210A2 (pt) 2011-05-24
NO20083722L (no) 2008-12-19
US20100021503A1 (en) 2010-01-28
EP2476434A1 (en) 2012-07-18
EA015833B1 (ru) 2011-12-30
AU2007233705B2 (en) 2010-12-23
KR20080111115A (ko) 2008-12-22
JP2009531387A (ja) 2009-09-03
US20180104323A1 (en) 2018-04-19
WO2007113222A2 (en) 2007-10-11
MY148405A (en) 2013-04-30
IL227934A (en) 2015-04-30
EA201101164A1 (ru) 2012-05-30

Similar Documents

Publication Publication Date Title
CR10348A (es) Composicion inmunogenica
AR056396A1 (es) Composicion inmunogenica
AR059330A1 (es) Composiciones acondicionadoras del cabello
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
WO2006032500A3 (en) Immunogenic composition
UY31789A1 (es) Composiciones de insulina de super rápida actuación
AR078601A1 (es) Composiciones inmunogenicas de antigenos de staphylococcus aureus
CL2012000744A1 (es) Proceso para preparar un conjugado de polisacáridos capsulares tipo 5 o tipo 8 de s. aureus y una molécula transportadora; conjugado de polisacáridos; y composición inmunogénica que lo comprende.
BRPI0515316A (pt) compostos de imidazoquinolina
CL2012000730A1 (es) Barra articulada en tres planos para el uso en implantes dentarios, la cual esta formada por un conjunto de brazos retractiles, en que un brazo es dotado de una extension que se encaja de forma deslizante en el brazo complementar, presentan un encaje concavo y/u otro encaje esferico.
AR060580A1 (es) Elastomeros de silicona que contienen antisepticos
BRPI0821240A2 (pt) formas mutantes de estreptolisina o
CL2012000392A1 (es) Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos para tratar cancer en combinacion con fludarabina .
AR101236A1 (es) Composiciones para el cuidado oral
NZ595223A (en) Combinations including pneumococcal serotype 14 saccharide
DK1965809T3 (da) Præparater til forbedring af sundhedstilstanden i dyrs tarmsystem og dyrs ydeevne omfattende Beta-glucanerne og Alfa-fucaner
AR056835A1 (es) Composicion que contiene oligosacaridos
AR098985A1 (es) Composiciones prebióticas para el cuidado oral contienen un alquilglucósido
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
WO2015028745A3 (fr) Composition cosmétique comprenant un polymère sulfonique, un polysaccharide hydrophobe et un tensioactif siliconé
UA97359C2 (en) Immunogenic composition
RS51896B (en) The use of glucose isomerase in the treatment of fructose intolerance
AR060182A1 (es) Polisacaridos capsulares tipo 5 y tipo 8 de cepas s. aureus de sobreproduccion
CU20110128A7 (es) Composiciones, métodos y usos para inducir el crecimiento viral
AR068815A1 (es) Soporte para corona dental provisional